Pre-earnings options volume in FibroGen is normal with calls leading puts 43:1. Implied volatility suggests the market is anticipating a move near 25.4%, or 0c, after results are released. Median move over the past eight quarters is 8.6%.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FGEN:
- FGEN Upcoming Earnings Report: What to Expect?
- FibroGen ends pamrevlumab R&D after study results, cutting 75% of U.S workers
- FibroGen: LAPIS study did not meet the primary endpoint of OS
- FibroGen trading resumes
- FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update